Skip to main content

Satsuma Pharmaceuticals, Inc.

STSADelisted Jun 8, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001692830

Satsuma Pharmaceuticals, Inc. was delisted on Jun 8, 2023; its insiders filed their last Form 4 on Jun 12, 2023; 31 institutions reported holding it in 13F filings for Q1 2023, worth $12.7M in total; no superinvestor held it.

Q2 2021 vs. Q1 2021

How the institutions holding Satsuma Pharmaceuticals, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of STSA: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders6160−1
Shares23.2M23.8M+591.3K (+2.6%)
Value$136.3M$167.4M+$31.1M (+22.8%)

New holders (12)

Institutions that held Satsuma Pharmaceuticals, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to STSA in Q2 2021
InstitutionSharesValue% of portfolio
Ameriprise Financial Inc646,190$4.56M0.00%
Gsa Capital Partners LLP53,231$375.0K0.04%
Ergoteles LLC42,000$296.0K0.01%
Tibra Equities Europe Ltd35,000$247.0K0.08%
Susquehanna International Group, LLP26,292$185.0K0.00%
Bailard, Inc.20,500$145.0K0.01%
Jump Financial, LLC18,700$132.0K0.01%
Marshall Wace North America L.P.18,642$131.0K0.00%
D. E. Shaw & Co., Inc.14,628$103.0K0.00%
ExodusPoint Capital Management, LP13,474$95.0K0.00%
Acadian Asset Management LLC4,736$33.0K0.00%
Captrust Financial Advisors128$1.00K0.00%

Sold out (13)

Institutions that held Satsuma Pharmaceuticals, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.